Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States
A U.S. policy initiative focused on regulating and potentially restricting the importation of foreign-made medicines and their raw components. Positively Impacted Sectors Domestic Pharmaceutical Manufacturers: Benefits from reduced foreign competition and potential "Buy American" procurement mandates. U.S. Specialty Chemical Producers: Increased demand for domestically synthesized Active Pharmaceutical Ingredients (APIs) and raw precursors. Domestic Medical Logistics and Cold Storage: Growth in local infrastructure needs for storing and distributing U.S.-made products. Contract Development and Manufacturing Organizations (CDMOs): High demand for U.S.-based facilities as companies onshore production to avoid import hurdles. Negatively Impacted Sectors Multinational Pharmaceutical Corporations: Higher operational costs and supply chain disruptions from moving production out of lower-cost foreign markets. International Generic Drug Manufacturers: Direct loss of ...